Literature DB >> 26601943

RNA Editing Modulates Human Hepatic Aryl Hydrocarbon Receptor Expression by Creating MicroRNA Recognition Sequence.

Masataka Nakano1, Tatsuki Fukami1, Saki Gotoh1, Masataka Takamiya2, Yasuhiro Aoki2, Miki Nakajima3.   

Abstract

Adenosine to inosine (A-to-I) RNA editing is the most frequent type of post-transcriptional nucleotide conversion in humans, and it is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes. In this study we investigated the effect of RNA editing on human aryl hydrocarbon receptor (AhR) expression because the AhR transcript potentially forms double-stranded structures, which are targets of ADAR enzymes. In human hepatocellular carcinoma-derived Huh-7 cells, the ADAR1 knockdown reduced the RNA editing levels in the 3'-untranslated region (3'-UTR) of the AhR transcript and increased the AhR protein levels. The ADAR1 knockdown enhanced the ligand-mediated induction of CYP1A1, a gene downstream of AhR. We investigated the possibility that A-to-I RNA editing creates miRNA targeting sites in the AhR mRNA and found that the miR-378-dependent down-regulation of AhR was abolished by ADAR1 knockdown. These results indicated that the ADAR1-mediated down-regulation of AhR could be attributed to the creation of a miR-378 recognition site in the AhR 3'-UTR. The interindividual differences in the RNA editing levels within the AhR 3'-UTR in a panel of 32 human liver samples were relatively small, whereas the differences in ADAR1 expression were large (220-fold). In the human liver samples a significant inverse association was observed between the miR-378 and AhR protein levels, suggesting that the RNA-editing-dependent down-regulation of AhR by miR-378 contributes to the variability in the constitutive hepatic expression of AhR. In conclusion, this study uncovered for the first time that A-to-I RNA editing modulates the potency of xenobiotic metabolism in the human liver.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  RNA editing; aryl hydrocarbon receptor (AhR) (AHR); cytochrome P450; drug metabolism; microRNA (miRNA)

Mesh:

Substances:

Year:  2015        PMID: 26601943      PMCID: PMC4705407          DOI: 10.1074/jbc.M115.699363

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  MiR-378 promotes the migration of liver cancer cells by down-regulating Fus expression.

Authors:  Jichun Ma; Jiang Lin; Jun Qian; Wei Qian; Jiayu Yin; Burton Yang; Qin Tang; Xingxing Chen; Xiangmei Wen; Hong Guo; Zhaoqun Deng
Journal:  Cell Physiol Biochem       Date:  2014-12-09

2.  Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities.

Authors:  K A Lehmann; B L Bass
Journal:  Biochemistry       Date:  2000-10-24       Impact factor: 3.162

3.  Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Authors:  Leilei Chen; Yan Li; Chi Ho Lin; Tim Hon Man Chan; Raymond Kwok Kei Chow; Yangyang Song; Ming Liu; Yun-Fei Yuan; Li Fu; Kar Lok Kong; Lihua Qi; Yan Li; Na Zhang; Amy Hin Yan Tong; Dora Lai-Wan Kwong; Kwan Man; Chung Mau Lo; Si Lok; Daniel G Tenen; Xin-Yuan Guan
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

Review 4.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

5.  Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3'-Untranslated Region Affect the Regulation of CYP2E1 by miR-570.

Authors:  Masataka Nakano; Takuya Mohri; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Howard L McLeod; Miki Nakajima
Journal:  Drug Metab Dispos       Date:  2015-07-21       Impact factor: 3.922

6.  Human CYP2E1 is regulated by miR-378.

Authors:  Takuya Mohri; Miki Nakajima; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Tsuyoshi Yokoi
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

7.  Interindividual difference in expression of human Ah receptor and related P450 genes.

Authors:  S Hayashi; J Watanabe; K Nakachi; H Eguchi; O Gotoh; K Kawajiri
Journal:  Carcinogenesis       Date:  1994-05       Impact factor: 4.944

Review 8.  A-to-I RNA editing and cancer: from pathology to basic science.

Authors:  Angela Gallo; Silvia Galardi
Journal:  RNA Biol       Date:  2008-07-05       Impact factor: 4.652

9.  ADAR2 A-->I editing: site selectivity and editing efficiency are separate events.

Authors:  Annika M Källman; Margareta Sahlin; Marie Ohman
Journal:  Nucleic Acids Res       Date:  2003-08-15       Impact factor: 16.971

10.  Adenosine deamination in human transcripts generates novel microRNA binding sites.

Authors:  Glen M Borchert; Brian L Gilmore; Ryan M Spengler; Yi Xing; William Lanier; Debashish Bhattacharya; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2009-09-23       Impact factor: 6.150

View more
  13 in total

Review 1.  Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.

Authors:  Charles E Samuel
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

2.  A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.

Authors:  Masataka Nakano; Tatsuki Fukami; Saki Gotoh; Miki Nakajima
Journal:  J Biol Chem       Date:  2017-02-10       Impact factor: 5.157

Review 3.  When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference.

Authors:  Yumeng Wang; Han Liang
Journal:  Bioessays       Date:  2017-12-27       Impact factor: 4.345

Review 4.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

Review 5.  ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer.

Authors:  Charles J Cho; Seung-Jae Myung; Suhwan Chang
Journal:  Int J Mol Sci       Date:  2017-04-11       Impact factor: 5.923

6.  Structure-mediated modulation of mRNA abundance by A-to-I editing.

Authors:  Anneke Brümmer; Yun Yang; Tracey W Chan; Xinshu Xiao
Journal:  Nat Commun       Date:  2017-11-02       Impact factor: 14.919

Review 7.  A Census and Categorization Method of Epitranscriptomic Marks.

Authors:  Julia Mathlin; Loredana Le Pera; Teresa Colombo
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

8.  ADAR Mediated RNA Editing Modulates MicroRNA Targeting in Human Breast Cancer.

Authors:  Justin T Roberts; Dillon G Patterson; Valeria M King; Shivam V Amin; Caroline J Polska; Dominika Houserova; Aline Crucello; Emmaline C Barnhill; Molly M Miller; Timothy D Sherman; Glen M Borchert
Journal:  Processes (Basel)       Date:  2018-04-25       Impact factor: 2.847

9.  Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells.

Authors:  Cristina Florean; Michael Schnekenburger; Jin-Young Lee; Kyung Rok Kim; Aloran Mazumder; Sungmi Song; Jae-Myun Kim; Cindy Grandjenette; Jeoung-Gyun Kim; Ah-Young Yoon; Mario Dicato; Kyu-Won Kim; Christo Christov; Byung-Woo Han; Peter Proksch; Marc Diederich
Journal:  Oncotarget       Date:  2016-04-26

Review 10.  Deciphering miRNAs' Action through miRNA Editing.

Authors:  Marta Correia de Sousa; Monika Gjorgjieva; Dobrochna Dolicka; Cyril Sobolewski; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.